KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) EBT (2020 - 2023)

AbCellera Biologics' EBT history spans 4 years, with the latest figure at -$48.6 million for Q4 2023.

  • For the quarter ending Q4 2023, EBT fell 54.72% year-over-year to -$48.6 million, compared with a TTM value of -$174.0 million through Dec 2023, down 172.79%, and an annual FY2024 reading of -$200.4 million, down 15.15% over the prior year.
  • EBT for Q4 2023 was -$48.6 million at AbCellera Biologics, down from -$39.3 million in the prior quarter.
  • The five-year high for EBT was $230.8 million in Q1 2022, with the low at -$48.6 million in Q4 2023.
  • Average EBT over 4 years is $28.0 million, with a median of -$2.4 million recorded in 2020.
  • Biggest YoY gain for EBT was 7815.58% in 2021; the steepest drop was 827.29% in 2021.
  • Tracing ABCL's EBT over 4 years: stood at $161.2 million in 2020, then plummeted by 47.44% to $84.7 million in 2021, then plummeted by 137.08% to -$31.4 million in 2022, then tumbled by 54.72% to -$48.6 million in 2023.
  • Per Business Quant, the three most recent readings for ABCL's EBT are -$48.6 million (Q4 2023), -$39.3 million (Q3 2023), and -$38.0 million (Q2 2023).